Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Multi-Center, Dose Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

NCT07610798 is registered in ClinicalTrials.gov with Shenzhen Ionova Life Sciences Co., Ltd. as lead sponsor.

NCT NCT07610798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Multi-Center, Dose Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
May 31, 2029
Enrollment
178 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advance solid tumors, biliary cancers, colon and rectal cancer, endometrial cancer, non - small cell lung cancer nsclc, ovarian cancer, pancreatic adenocarcinoma advanced or metastatic